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OBJECTIVE: In the MOSAIC trial, oxaliplatin/5-ﬂuoruracil/leu-
covorin (FOLFOX4) as adjuvant treatment of stage III colon
cancer improved disease-free survival (DFS) at 4 years, compared
to 5-ﬂuorouracil/leucovorin (LV5FU2) (69.7% vs. 61.0%, p =
0.002). We analysed the cost-effectiveness of FOLFOX4 in the
UK and Germany to a lifetime horizon, from a payer perspec-
tive. METHODS: We developed Kaplan-Meier estimates of DFS
and overall survival (OS) to 4 years. DFS was extrapolated from
4 to 5 years with a Weibull model and thereafter from life tables,
adjusting for age and gender, assuming no relapses after 5 years.
Using DFS and observed survival after relapse, we predicted life-
time OS. Life-years accrued were assigned weights according to
chemotherapy-related toxicities, recurrence and age, to estimate
QALYs. Costs were estimated from trial data, accounting for
censoring; while costs of relapse and subsequent management
were estimated from literature. Costs and QALYs, discounted at
3.5% and 5% per annum for the UK and Germany respectively,
were bootstrapped to estimate the ICER distribution. RESULTS:
Patients on FOLFOX4 gained an estimated mean 0.68 (95% CI:
0.08–1.31) QALYs for the UK and 0.57 (95% CI: 0.04–1.10)
for Germany, at mean incremental costs of £3267 and £5844
respectively, resulting in mean ICERs of £4805 per QALY gained
for the UK and €10,199 for Germany. If the willingness to pay
for additional QALYs were £20,000 in the UK and €50,000 in
Germany, FOLFOX4 would be cost-effective with probabilities
of 95% and 96% in these countries respectively. CONCLU-
SIONS: If the estimated survival beneﬁt of oxaliplatin is con-
ﬁrmed, FOLFOX4 would cost around £4800 (approx. €6,700)
per QALY gained in the UK and €10,200 in Germany, well
within conventional limits of acceptability. The difference
between countries was largely attributable to the discount rates
used rather than differences in organisation of health care.
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OBJECTIVES: To estimate the cost-effectiveness (CE) of con-
comitant and adjuvant Temozolomide (TMZ) in glioblastoma
(GBM) compared to initial radiotherapy (RT) alone, based on
the UK health care system. METHODS: A cost-effectiveness
analysis (CEA) from the perspective of the National Health
Service has been performed. Data were derived from a large
EORTC/NCIC phase III trial (Stupp et al., NEJM 2005). The
primary endpoint was overall survival. As there was no negative
impact of the experimental treatment on quality of life, life years
were not adjusted. Costs included all direct medical costs. Eco-
nomic data were collected prospectively for a subgroup of 224
patients (39%). Unit costs for (chemo)drugs, procedures, labo-
ratory and imaging, RT, surgery and hospital costs per day were
collected from the ofﬁcial national reimbursement lists based on
2004. For the CEA, the life-years of patients were expressed as
2-year restricted mean estimates, as well as mean survival esti-
mates based on statistical extrapolations of the survival curves.
The Incremental Cost Effectiveness Ratio (ICER) has been con-
structed. Conﬁdence intervals for the ICER were calculated using
Fieller’s method and using bootstrapping, graphically presented
on the CE plane and a CE acceptability curve is constructed. A
discount rate of 3.5% was used for both costs and effects.
RESULTS: The difference in 2-year restricted survival between
the treatment arms was 0.17 life-years and the ICER was
≥28,418 per life-year gained. The extrapolated difference in sur-
vival was 0.45 life-years and the ICER amounted to ≥19,161 per
life-year gained. For the full cohort, the ratios obtained were
similar, but lower than those of the economic subgroup, due to
subgroup selection factors that resulted in different 2-year
restricted survival beneﬁts. CONCLUSION: The results showed
that treatment with concomitant RT plus TMZ may provide
good value for money in this difﬁcult indication in the UK.
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OBJECTIVES: To assess the cost–effectiveness of anastrozole
(ArimidexTM) as adjuvant treatment in postmenopausal hormone
receptor positive (HR+) early breast cancer (EBC). METHODS:
A Markov state transition model was created to simulate the
natural history of postmenopausal HR+ EBC over 20 years.
Adverse events and direct rates of disease progression were
obtained from the 5–year analysis of the ATAC (Arimidex,
Tamoxifen Alone or in Combination) trial (n = 9,366). Progres-
sion to subsequent health states following initial disease pro-
gression was based on published clinical studies. Utility scores
for different disease stages were obtained from published litera-
ture. Costs of breast cancer recurrence (locoregional and distant)
were obtained from a retrospective chart review (1998) which
was updated and validated by clinical expert opinion (2001).
Costs were discounted at 3%/y. Base–case analysis considered
Arimidex large pack price (€3.4286/day). RESULTS: Compari-
son with EBCTCG (Early Breast Cancer Trialists Collaborative
Group) data shows that the model is valid for predicting clini-
cal outcomes. At a life time horizon of 20 years, an incremental
cost-effectiveness ratio (ICER) of €4233/life year gained (LYG)
and €3958/QALY are obtained for anastrazole relative to tamox-
ifen. Conclusions were robust to variations in cost estimates of
disease progression and of risk reduction by anastrozole with
highest sensitivity to distant recurrence risk reduction. Outcomes
were sensitive to the applied time horizon with an ICER of
€8,474/LYG and €7581/QALY at 15 years and €26,758/LYG and
€21,770/QALY at 10 years. For the Arimidex small pack price
(€4.5611/day), ICERs are higher but remain below €30,000/LYG
or QALY for a time horizon of at least 12 years. CONCLUSION:
In adjuvant treatment ICERs are time horizon dependent due to
different timings of treatment costs (initial 5 years) and beneﬁts
